A196170 Stock Overview
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ALTEOGEN Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩178,300.00 |
| 52 Week High | ₩225,500.00 |
| 52 Week Low | ₩38,000.00 |
| Beta | 1.07 |
| 1 Month Change | -16.49% |
| 3 Month Change | 142.26% |
| 1 Year Change | 293.60% |
| 3 Year Change | 153.51% |
| 5 Year Change | 1,355.51% |
| Change since IPO | 5,870.98% |
Recent News & Updates
Recent updates
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?
Feb 29
ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability
Apr 13Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Feb 18
Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?
Dec 27Shareholder Returns
| A196170 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 10.9% | 4.1% | 0.5% |
| 1Y | 293.6% | 6.6% | 4.7% |
Return vs Industry: A196170 exceeded the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A196170 exceeded the KR Market which returned 4.7% over the past year.
Price Volatility
| A196170 volatility | |
|---|---|
| A196170 Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A196170's share price has been volatile over the past 3 months.
Volatility Over Time: A196170's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 128 | Soon-Jae Park | www.alteogen.com |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.
ALTEOGEN Inc. Fundamentals Summary
| A196170 fundamental statistics | |
|---|---|
| Market cap | ₩9.45t |
| Earnings (TTM) | -₩3.37b |
| Revenue (TTM) | ₩96.52b |
97.9x
P/S Ratio-2,802x
P/E RatioIs A196170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A196170 income statement (TTM) | |
|---|---|
| Revenue | ₩96.52b |
| Cost of Revenue | ₩65.38b |
| Gross Profit | ₩31.14b |
| Other Expenses | ₩34.51b |
| Earnings | -₩3.37b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -63.63 |
| Gross Margin | 32.26% |
| Net Profit Margin | -3.49% |
| Debt/Equity Ratio | 0.5% |
How did A196170 perform over the long term?
See historical performance and comparison